Zeo ScientifiX completes Phase 1 trials for Zofin; seeks Phase 2 trials

Zeo ScientifiX, Inc.

Completed Phase 1 clinical trials for flagship product Zofin; actively seeking to commence Phase 2 trials for multiple indications.
Partnered with Exotropin to develop topical aesthetic and anti-aging products using exosome technology; holds minority stake.
Changed name from Organicell Regenerative Medicine to Zeo ScientifiX in February 2024 to reflect scientific focus.
Regenerative medicine market projected to grow to $175B by 2032 at 22.8% CAGR, per Precedence Research.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.